ijms-logo

Journal Browser

Journal Browser

New Strategy on Diagnosis and Treatment of Meningioma and Glioma

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 30 November 2025 | Viewed by 5

Special Issue Editor

Special Issue Information

Dear Colleagues,

Meningiomas and gliomas represent the most prevalent primary tumors of the central nervous system, encompassing a wide clinical and biological spectrum. Recent advances in molecular biology, neuroimaging, and personalized medicine have led to novel diagnostic and therapeutic strategies that are currently reshaping clinical management. This Special Issue aims to highlight cutting-edge research in the molecular characterization, biomarker discovery, and targeted treatment approaches for both meningioma and glioma. We welcome original research articles, reviews, and clinical studies that explore innovative imaging modalities, molecular profiling techniques, experimental therapies, and translational insights that may improve diagnosis, prognostication, and treatment outcomes. Contributions addressing challenges in recurrent or high-grade cases, resistance mechanisms, and the integration of artificial intelligence are particularly encouraged. This Special Issue aspires to provide a comprehensive overview of current progress and future directions in the evolving landscape of meningioma and glioma care.

Dr. Giuseppe Lombardi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • meningiomas
  • gliomas
  • molecular characterization
  • biomarker discovery
  • targeted therapy
  • neuroimaging
  • artificial intelligence

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers

This special issue is now open for submission.
Back to TopTop